

ClaimsSub
B3

1. A method for antigen independent activation of T cells comprising contacting T cells with a combination of cytokines.
2. The method of claim 1, wherein the T cells are contacted with at least two of the following:
 - i) interleukin-2;
 - ii) interleukin-6; and
 - iii) tumour necrosis factor α
 or functionally equivalent fragments thereof.
3. The method of claim 1 or 2, wherein the T cells are naive T cells and/or memory resting T cells.
4. The method of ^{claim} ~~any one of claims 1 to 3~~, wherein the T cells are naive CD45RA⁺ cells and/or memory resting CD45RO⁺ cells.
5. The method of ^{claim 1} ~~any one of the preceding claims~~, wherein the concentration of interleukin-2 is from 100 to 400 U/ml, the concentration of interleukin-6 is from 400 to 600 U/ml and the concentration of tumour necrosis factor α is from 15 to 35 ng/ml.
6. The method of ^{claim 1} ~~any one of the preceding claims~~, wherein the concentration of interleukin-2 is from 200 to 300 U/ml, the concentration of interleukin-6 is about 500 U/ml and the concentration of tumour necrosis factor α is about 25 ng/ml.
7. ~~The method of any one of the preceding claims, wherein T cells are activated in vitro.~~
8. A method for obtaining increased lymphokine production

002000-04202500

